Redx Pharma's competitors

Redx Pharma's competitors include Biogen, MyoKardia, Alimera Sciences and Otonomy
Add company...
Redx Pharma
Redx Pharma is a leading UK biotech developing new drugs to treat cancer, infectious diseases and a range of other health issues.
Biogen
Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Alimera Sciences
Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Founding Date
Founding Date
2010
Founding Date
1978
Founding Date
N/A
Founding Date
2003
Founding Date
2008
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Liverpool, GB HQ
Cheshire East, GB
Locations
Cambridge, US HQ
Locations
South San Francisco, US HQ
Locations
Alpharetta, US HQ
Berlin, DE
Lisbon, PT
Hampshire, GB
Locations
San Diego, US HQ
Employees
Employees
145
Employees
7,300 1% decrease
Employees
98
Employees
125
Employees
139
Valuation ($)
Valuation ($)
39.2 m
Valuation ($)
62.2 b
Valuation ($)
1.9 b
Valuation ($)
87.6 m
Valuation ($)
175.8 m
Facebook followers
Facebook followers
N/A
Facebook followers
2.7 k
Facebook followers
N/A
Facebook followers
3.5 k
Facebook followers
1.1 k
Twitter followers
Twitter followers
985
Twitter followers
18.5 k
Twitter followers
370
Twitter followers
1.7 k
Twitter followers
270

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$11.4b (FY, 2016)
Revenue (est.)
$39.2m (FY, 2016)
Revenue (est.)
$34.3m (FY, 2016)
Revenue (est.)
$683k (FY, 2016)
Net income
Net income
(£15.5m) (FY, 2016)
Net income
$3.7b (FY, 2016)
Net income
($13.2m) (FY, 2016)
Net income
($33.2m) (FY, 2016)
Net income
($110.6m) (FY, 2016)

Operating

Phase I Trials
Phase I Trials
N/A
Phase I Trials
4 (FY, 2016)
Phase I Trials
N/A
Phase I Trials
N/A
Phase I Trials
1 (FY, 2016)
Phase II Trials
Phase II Trials
N/A
Phase II Trials
10 (FY, 2016)
Phase II Trials
N/A
Phase II Trials
N/A
Phase II Trials
2 (FY, 2016)
Phase III Trials
Phase III Trials
N/A
Phase III Trials
2 (FY, 2016)
Phase III Trials
N/A
Phase III Trials
N/A
Phase III Trials
2 (FY, 2016)
For sources of this data, please see the company profileDownload Excel

View company profiles